Danaher Corporation has completed a planned executive succession, installing Julie Sawyer Montgomery as president and chief executive officer effective October 1, 2026. The handover places the new Danaher CEO in charge just weeks before the life sciences group reports its third-quarter 2026 results, putting her straight into the spotlight with investors.
What the New Danaher CEO Inherits
Sawyer Montgomery joined Danaher in 2017 and played a central role in transforming the company’s Diagnostics platform into a market-leading franchise. Under her stewardship, the business grew from roughly 6 billion dollars in revenue in 2017 to about 11 billion dollars today, while approximately tripling operating profit, according to the company’s announcement.
That track record matters because Danaher is navigating a cyclical turn in life sciences demand. In its second-quarter report, the company projected full-year 2026 core revenue growth of 3 to 4 percent, after biopharmaceutical customers deferred delivery of roughly 100 million dollars in bioprocessing equipment and resin shipments into 2027.
Succession Plan Executed on Schedule
The change was not a surprise to the market. Danaher first communicated the executive succession plan on August 3, 2026, and the board’s formal appointment took effect on October 1 exactly as scheduled.
Former president and chief executive Rainer Blair stepped down from his executive duties but will remain with the company as a senior advisor through March 31, 2027, to ensure a seamless transition, the company said.
Chairman Steven Rales backed the appointment, saying Sawyer Montgomery has “the vision, experience, and proven track record to deliver” on the company’s growth potential, citing her commitment to innovation, commercial excellence and operational rigor.
Earnings Test Set for October 21
Danaher has scheduled its third-quarter 2026 earnings conference call for October 21, 2026. The update will give investors the first detailed read on performance under the new chief executive, covering demand in biotechnology, diagnostics and life sciences.
Analysts remain broadly constructive. Guggenheim raised its Danaher price target from 200 to 250 dollars on October 1, keeping a Buy rating, while MarketBeat lists a Strong Buy consensus across 25 analysts with an average 12-month price target near 232 dollars.
Shares fell on the transition day, closing at 211.71 dollars on October 1, down 4.5 percent, as investors weighed near-term execution risk during the management change against the company’s longer-term growth story.
FAKTA
- Julie Sawyer Montgomery became president and CEO of Danaher on October 1, 2026, and joined the board of directors.
- Former CEO Rainer Blair retired from executive duties and will serve as senior advisor through March 31, 2027.
- Under Montgomery, the Diagnostics platform grew from about 6 billion to about 11 billion dollars in revenue since 2017.
- Danaher reports third-quarter 2026 results on October 21, 2026.
- The company guides full-year 2026 core revenue growth of 3 to 4 percent.
Conclusion
Danaher’s succession gives the life sciences group a diagnostics-proven insider at a moment when demand recovery matters more than promises. Whether the new Danaher CEO can convert the diagnostics playbook into enterprise-wide growth will be tested as early as October 21, when third-quarter numbers land.
For more coverage of global business leadership and corporate transitions, visit the Watan News International English edition.
